EFDID: 560457EFD: View Filing

Issuer: Quince Therapeutics, Inc. (0001662774) - D

Accession: 0001662774-25-000035 (XMLRaw Data) (EDGAREDGAR Files) (Form DForm D)

EDGAR: Issuer Information
  • CIK:
    0001662774
  • Entity Name:
    Quince Therapeutics, Inc.
  • Entity Type:
    Corporation
  • Jurisdiction:
    CALIFORNIA
  • Year of Inc:
    Over 5 years ago
  • Address:
    611 GATEWAY BLVD., SUITE 273
    SOUTH SAN FRANCISCO, CA 94080
  • Persons:
    Related Persons 10
    Dirk Thye
    Executive Officer, Director
    Charles Ryan
    Executive Officer
    David Lamond
    Director
    Margi McLoughlin
    Director
    Christopher Senner
    Director
    Luca Benatti
    Director
    Rajiv Patni
    Director
    June Bray
    Director
    Una Ryan
    Director
    Brendan Hannah
    Executive Officer
EDGAR: Offering Information
  • Accession Date:
    07/01/2025
  • First Sale Date:
    06/18/2025
  • Offering Amount:
    $21,896,618
  • Amount Sold:
    $11,488,304
  • Amount Remaining:
    $10,408,314
  • Exemptions:
    Rule 506
  • Security Type(s):
    Equity
  • Sales Clarification:
    Offering amount includes (a) gross proceeds from sale of shares of common stock, pre-funded warrants and common warrants and (b) an aggregate gross proceeds that may be received in the future upon the cash exercise in full of the warrants.
EFD: Current State Notices
View Notices

Notices found in EFD

Filed:CA, CT, DE, NC, NV, NY, PA, TN, TX
EDGAR: Sales Compensation Recipient Information
RecipientCRDBroker DealerBD CRDStates
Citizens JMP Securities, LLC 22208 None None CA, CT, FL, IL, MD, MA, NV, NY, OR, TN, TX, WA
EDGAR: Signatures
IssuerSignatureSigner NameTitleSignatureDate
Quince Therapeutics, Inc./s/ Brendan HannahBrendan HannahChief Business Officer2025-07-01